Press Release
December 14, 2021

WhizAI Raises $8M in Series A Financing to Bring the Future of Analytics to the Life Sciences Industry.

WhizAI Raises $8M in Series A Financing to Bring the Future of Analytics to the Life Sciences Industry.

Somerset, NJ, Dec 14, 2021  WhizAI, the first and only purpose-built, augmented consumer platform for the life sciences industry, raised $8 million in series A financing. 

Vertical Venture Partners led this round; existing investors also participated. This latest investment brings the total amount raised by the company to over $15 million.

WhizAI is transforming how top global pharma companies use analytics to increase the top line and reduce the bottom line. They help large and mid-sized pharma:

  • reduce TCO by~50% while modernizing and streamlining legacy analytics systems through intelligent automation
  • empower business users in sales, commercial ops, marketing,R&D, and supply chain through contextual, actionable insights without month-long wait times and complex software that needs high-level technical skills
  • improve business outcomes by identifying key opportunities, eliminating operational inefficiencies, and streamlining the analytics ecosystem

All this is possible because WhizAI is exclusive to the life sciences industry. The AI is pre-trained in the language, domain, and analytics to deliver timely, specific insights. 

“We are fundamentally changing the way analytics is done in life sciences by helping our customers keep pace with large scale data, on-demand analytics, and timely insights. The future of analytics is augmented via AI to enable everyone to be insights-driven. We are delighted that our investors share this vision and support us to fulfill our mission. We will be using this investment to expand our footprint in the US and Europe and invest in all aspects of the business.” said Rohit Vashisht, co-founder and CEO, WhizAI.

David Schwab, Founder and Managing Director at Vertical Venture Partners, adds: “BI is another horizontal platform technology that needs to move to vertical-specific for customers to get the full value. Predictive and prescriptive analytics, the next phase of customer value from BI, cannot be fully realized without a vertical approach. This move from horizontal platforms to vertical solutions is the core theme of our venture fund. This vertical approach combined with a strong management team with deep BI experience makes this an ideal investment for Vertical Venture Partners.”

Through its combination of NLP, machine learning, visualization, and data scalability, WhizAI is a leap forward in business intelligence software for life sciences. The company will use the capital to grow its industry footprint by expanding its team across the globe and investing in sales and marketing so that more companies can get the fast, easy, and contextual insights necessary to compete. To learn more, please visit

 About WhizAI: WhizAI is the first and only augmented consumer platform purpose-built for the life sciences industry. It puts insights directly into the hands of business users empowering decision-makers to drive more informed and faster business decisions at a lower cost. With its deep understanding of the life sciences domain and user intent, the platform delivers insights without the delays of traditional BI dashboards. Fast, easy, and scalable,WhizAI is transforming analytics with artificial intelligence optimized for life sciences making WhizAI the trusted partner of choice at top global life sciences companies. Learn more about

Contact: Rick Clements, Head of Marketing

People also viewed